NEOADJUVANT PUBLICATIONS & ABSTRACTS

Neoadjuvant data


Neoadjuvant publications

Evidence / Neoadjuvant

Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2 – breast cancer

Publication: npj Breast Cancer, Article number: (2026) Authors: Sonya Reid; Lindsay Venton; Jennifer G. Whisenant; Anne E. Weidner; Jennifer Wei; Harshini Ramaswamy; Christa Dreezen; Nicole Chmielewski-Stivers;Andrea R. Menicucci; William Audeh; Tuya Pal Title: Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2 – breast cancer Abstract: We Read More

Impact of Neoadjuvant Endocrine Therapy on MammaPrint Index in Hormone Receptor–Positive, HER2-Negative MammaPrint Low Risk Early-Stage Breast Cancer

Publication: SABCS 2025 Authors: Saya Jacob, Cynthia Wu, Annuska Glas, Christina Yau, Lamorna Brown-Swigart, Gillian Hirst, Tufia Haddad, Karthik Giridhar, Anthony Elias, Rita Mukhtar, Laura Huppert, Kathy Albain, Doug Yee, Laura van’t Veer, Laura Esserman2, Jo Chien Title: Distinct Immune and Metabolic profiles in Latin American Breast Cancer Patients Read More

HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study

Publication: SABCS 2025, Presentation ID: PS3-08-17 Authors: Mahtani et al. Title: HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study Introduction: Women ≥ 70 years of age are less likely to receive chemotherapy (CT) due to Read More

70-Gene Signature High Risk Classification Provides Stronger Prognostic Value Than Histologic Grade in HR+HER2– Early Breast Cancer

Publication: SABCS 2025, Presentation ID: PS5-04-19 Authors: Cobain et al. Title: Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2- early-stage breast cancer Introduction: Pivotal trials of immunotherapy and CDK4/6 inhibitors in early-stage hormone-receptor positive (HR+) HER2 negative (HER2–) breast cancer have Read More

Personalized Neoadjuvant Strategy Using 70-Gene Assay To Increase Breast-Conserving Surgery in ER+/HER2– Breast Cancer

Publication:NPJ Breast Cancer, 20 June 2025 Authors: W. Han, et al. Title: Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer Abstract We investigated whether tailored neoadjuvant therapy (chemotherapy [NCT] or endocrine therapy [NET]) guided by a 70-gene assay could improve breast-conserving surgery (BCS) Read More

Real-World Evidence From FLEX: Utility of MammaPrint in Guiding Treatment Planning for Patients Aged 70 and Older With Early-Stage Breast Cancer

Publication: ASCO® 2025 Authors: Reshma Mahtani, Ana Sandoval-Leon, Anna Schrieber, Cathy Graham, Lauren Carcas, Naomi Dempsey, Victoria Poillucci, Michelle Landon, Christa Dreezen, William Audeh Title: Real-world Evidence from FLEX: Utility of MammaPrint in guiding treatment planning for patients aged 70 and older with early-stage breast cancer Background: Older women Read More

Molecular Insights Into HR+/HER2+ Early-Stage Breast Cancer: Neoadjuvant Therapy Responses by MammaPrint and BluePrint Genomic Subtypes

Publication: ASCO® 2025 Authors: Laila Samiian, Adam Brufsky, Sahra Uygun, Isha Kapoor, Victoria Poillucci, Joyce O’Shaughnessy, William Audeh Title:Molecular Insights into HR+/HER2+Early-Stage Breast Cancer: Neoadjuvant Therapy Responses by MammaPrint and BluePrint genomic subtypes Background: Clinical HER2+ (cHER2+) early breast cancer (EBC) represents 15-20% of invasive EBC and is typically Read More